Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11515705 | 0.92 | CA1 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27653505 | 0.89 | CA1 (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11725822 | 0.86 | CA1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12948025 | 0.85 | CA1 (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL22134463 | 0.83 | MAPT (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4930245 | 0.82 | MAPT (0.69) | CA1CA2MAPTTP53ALDH1A1 | |
| SCHEMBL6538953 | 0.82 | CA1 (0.81) | CA1CA2CA12CA7CA9 | |
| SCHEMBL13949650 | 0.82 | RAB9A (0.53) | TP53ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL969070 | 0.81 | MAPT (0.72) | CA1CA2CA12CA7CA9 | |
| SCHEMBL22134464 | 0.80 | MAPT (0.47) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-20200087342-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3256483-A2 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2017-12-20 | — | — | EP | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | IL17A, CDK17, CCR3 | CA1 4513/4885CA2 4334/4885CA12 3974/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | CA1 4592/4885CA2 3320/4885CA12 4836/4885 |
| US-20200087342-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | IL17A, CDK17, CCR3 | CA1 4513/4885CA2 4334/4885CA12 3974/4885 |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | CA1 4471/4885CA2 4321/4885CA12 3589/4885 |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | CA1 4597/4885CA2 4427/4885CA12 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.